Skip to main content
main-content

28.07.2017 | REVIEW ARTICLE | Ausgabe 3/2017 Open Access

Cardiovascular Drugs and Therapy 3/2017

MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications

Zeitschrift:
Cardiovascular Drugs and Therapy > Ausgabe 3/2017
Autoren:
Nicoline W. E. van den Berg, Makiri Kawasaki, Wouter R. Berger, Jolien Neefs, Eva Meulendijks, Anke J. Tijsen, Joris R. de Groot
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s10557-017-6736-z) contains supplementary material, which is available to authorized users.
SEARCH
A systematic search was performed in OVID MEDLINE (31–10-2016) to identify relevant articles. We excluded articles in Chinese or poor quality articles. We included human and animal studies. The search terms included synonyms for “atrium”, “atrial fibrillation” and “microRNAs”. (Details Online Resource)

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with pronounced morbidity and mortality. Its prevalence, expected to further increase for the forthcoming years, and associated frequent hospitalizations turn AF into a major health problem. Structural and electrical atrial remodelling underlie the substrate for AF, but the exact mechanisms driving this remodelling remain incompletely understood. Recent studies have shown that microRNAs (miRNA), short non-coding RNAs that regulate gene expression, may be involved in the pathophysiology of AF. MiRNAs have been implicated in AF-induced ion channel remodelling and fibrosis. MiRNAs could therefore provide insight into AF pathophysiology or become novel targets for therapy with miRNA mimics or anti-miRNAs. Moreover, circulating miRNAs have been suggested as a new class of diagnostic and prognostic biomarkers of AF. However, the origin and function of miRNAs in tissue and plasma frequently remain unknown and studies investigating the role of miRNAs in AF vary in design and focus and even present contradicting results. Here, we provide a systematic review of the available clinical and functional studies investigating the tissue and plasma miRNAs in AF and will thereafter discuss the potential of miRNAs as biomarkers or novel therapeutic targets in AF.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Zusatzmaterial
ESM 1 (DOC 57 kb)
10557_2017_6736_MOESM1_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2017

Cardiovascular Drugs and Therapy 3/2017 Zur Ausgabe

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise